VCYT250117P45000
- 4.90
- 0.000.00%
Veracyte Newsroom
Goldman Sachs Downgrades Veracyte(VCYT.US) to Hold Rating
Goldman Sachs Downgrades Veracyte to Neutral, Lowers Price Target to $37
Veracyte Is Maintained at Underweight by Morgan Stanley
Veracyte Price Target Raised to $28.00/Share From $26.00 by Morgan Stanley
Veracyte Analyst Ratings
Sell Rating on Veracyte: Strong Performance Overshadowed by Limited Immediate Upside
Wolfe Research Initiates Veracyte(VCYT.US) With Buy Rating, Announces Target Price $50
Veracyte Initiated With an Outperform at Wolfe on Growth, Margin Potential
Veracyte Initiated With an Outperform at Wolfe Research
Leerink Partners Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $50
Scotiabank Maintains Veracyte(VCYT.US) With Buy Rating, Raises Target Price to $44
A Quick Look at Today's Ratings for Veracyte(VCYT.US), With a Forecast Between $38 to $50
Scotiabank Reaffirms Their Buy Rating on Veracyte (VCYT)
Veracyte Is Maintained at Buy by Goldman Sachs
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Raises Target Price to $44
Veracyte's Strong Financial Performance and Growth Potential Lead to Buy Rating and Increased Price Target
Veracyte Analyst Ratings
Needham Maintains Buy on Veracyte, Raises Price Target to $44
Leerink Partners Maintains Veracyte(VCYT.US) With Buy Rating, Raises Target Price to $40
UBS Initiates Veracyte(VCYT.US) With Buy Rating, Announces Target Price $43